Loading
LOADING
For research subjects with prior GLP-1 exposure who tolerated semaglutide well. Faster escalation than the standard SURMOUNT protocol because baseline GI tolerance is already established.
Not for first-time GLP-1 research. The slow titration matters for new exposure.
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| Tirzepatide | 5mg → 10mg → 15mg | Weekly | SubQ |
No comments yet. Start the thread.